Nine years ago, researchers from the Southwest Oncology Group (SWOG) confirmed the new standard of care for patients with incurable malignant stromal tumor of the gastrointestinal tract imatinib mesylate, a drug marketed under the trade name Gleevec. Scientists spoke about the results of the work, it is estimated that one out of four patients taking Glivec, life expectancy increased by 10 years. The results of the study published in JAMA Oncology.
This is an amazing discovery, says Michael Heinrich, professor of medicine and of cell biology. Gleevec is not yet appeared, life expectancy of patients was 18 months. Now we have learned that some may live for ten years or longer, and knew exactly how Glivec patients benefit most.
Scientists report on the health status of patients initially included in the S0033 program, phase III trial, which began in 2000. The initial results, published in 2008, confirmed that Gleevec effective treatment for patients with gastrointestinal tumors in an advanced stage, and recommended to start treatment with 400 mg per day. A team of scientists collected data from 2011 to 2015. In the study, experts used sequencing (sequencing) DNA on some samples of tumor tissue taken from the patient group S0033. Scientists have studied tissue 20 patients originally classified as having wild type tumor i.e. KIT gene mutations without affecting the cancer in 85-88 percent of cases.
The analysis showed that of the 695 patients included in the S0033 program, 189 have lived eight years longer, with the assessment of overall survival was 23 percent. DNA sequencing showed that the survival is significantly higher in patients with complete Exon-11 mutant tumor cells compared with those who had a mutation of KIT gene exon 9 KIT mutation or gene without mutations.
The results led to two discoveries, Henry says. Gleevec is the new solution for the treatment of patients with advanced cancer. The results of the study highlight the importance of patient data stored in the preparation of the scientific results, and that the tumor mutation testing can improve treatment.
Malignant tumor stromal gastrointestinal common type tumors due to the type of tissue in which they occur. Swelling refers to the group of cancers called soft tissue sarcoma. Sarcoma of soft tissue develops in the muscles, nerves, tendons, and joints. In the US diagnosed each year 6,000 new cases of this cancer.
The first scientists to try to win the tumor, were researchers from the Oregon Health and Science University. They have done important work in the study of Glivec and its use in the treatment of tumors of the gastrointestinal tract, chronic myeloid leukemia and acute lymphoblastic leukemia .